Who is sponsoring NCT05940051?

NCT05940051 is sponsored by Peng Liu.

What drugs are being tested in NCT05940051?

Interventions in NCT05940051: Zanubrutinib, Polatuzumab vedotin and Rituximab.

What condition does NCT05940051 study?

NCT05940051 studies Diffuse Large B Cell Lymphoma.

Is NCT05940051 still recruiting?

NCT05940051 is currently status unknown. Last updated 11 July 2023.

Last reviewed 2023-07-11 · How we verify

NCT05940051

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Status unknown Phase 2 Last updated 11 July 2023

What this trial tests

Phase 2 trial testing Zanubrutinib, Polatuzumab vedotin and Rituximab in Diffuse Large B Cell Lymphoma in 35 participants. Status unknown.

Timeline

20 July 2023

Primary endpoint
1 July 2025

30 December 2025

Quick facts

Lead sponsor	Peng Liu
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	20 July 2023
Primary completion	1 July 2025
Estimated completion	30 December 2025
Sites	1 location across China

Drugs / interventions tested

Zanubrutinib, Polatuzumab vedotin and Rituximab — full drug profile →

Conditions studied

Diffuse Large B Cell Lymphoma — all drugs for Diffuse Large B Cell Lymphoma →

Sponsor

Peng Liu — full company profile →

Who can join

Adults 18 to 80, any sex, with Diffuse Large B Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, single-arm, single-center clinical study. This clinical study aims to explore the efficacy and safety of the ZPR（Zanubrutinib, Polatuzumab vedotin and Rituximab）regimen in the treatment of patients with relapsed and refractory diffuse large B-cell lymphoma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice.
Tavarozzi R, Zacchi G, Pietrasanta D, Catania G, et al · · 2023 · cited 7× · PMID 38001657 · DOI 10.3390/cancers15225397
Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti-CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Zhang Y, Ren Y, Zhuang J, Yuan L, et al · · 2025 · cited 1× · PMID 40827409 · DOI 10.1002/cam4.71162

Verify or expand the search:

Other recruiting trials for Diffuse Large B Cell Lymphoma

Currently open trials in the same condition.

NCT06687772 — CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant · Phase 2 · recruiting
NCT06208735 — CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies · Phase 1 · recruiting
NCT06736613 — A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma · Phase 2 · recruiting
NCT06552572 — Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy · Phase 2 · active not recruiting
NCT06550141 — Emapalumab Prevention of CAR-T Cell Associated Toxicities · Phase 2 · recruiting

Other Peng Liu trials

Trials by the same sponsor.

NCT05940064 — Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma · Phase 2 · unknown
NCT05816694 — The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin · Phase 2 · not yet recruiting
NCT03605056 — Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM · Phase 2 · unknown
NCT06561997 — Enhancing Thoracolumbar Burst Fracture Treatment · completed
NCT06124170 — Improved Pain Management in Knee Osteoarthritis-related Surgeries · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05940051 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peng Liu
Last refreshed: 11 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05940051.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing